法国,西班牙,中国,韩国和日本的荷尔蒙敏感前列腺癌患者的治疗偏好:一个离散选择实验
Juan Marcos Gonzalez1,2,3, Arijit Ganguli4, Alicia K Morgans5
1Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
MDM policy & practice
|November 12, 2025
概括
患者对前列腺癌治疗的偏好在五个国家表现出了显著的一致性,治疗疗效是主要的驱动因素. 确定了两个不同的患者偏好类别,突出了改善患者-临床医生沟通的必要性.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 行为科学 行为科学
背景情况:
- 患者对高风险局部性前列腺癌 (HRLPC) 和转移性激素敏感前列腺癌 (mHSPC) 治疗的偏好可能在全球范围内有所不同.
- 各国的文化和制度差异可能会影响这些偏好.
- 量化治疗结果的重要性对于了解患者需求至关重要.
研究的目的:
- 评估五个不同国家的HRLPC和mHSPC患者治疗偏好的一致性.
- 量化患者对各种治疗结果和属性的重视程度.
主要方法:
- 在法国,西班牙,中国,韩国和日本,对被诊断患有HRLPC或mHSPC的成年患者进行了离散选择实验 (DCE) 调查.
- 一个潜在类随机参数逻辑模型被用来分析患者的偏好和确定偏好类.
- 这项研究包括了有或没有先前的雄激素缺乏治疗经验的患者.
主要成果:
- 共有468名患者完成了调查.
- 确定了两个主要的患者偏好类别,约占受访者的80%.
- 治疗疗效成为患者偏好的最重要的驱动因素,超过了皮肤皮疹,疲劳,类固醇使用或化疗副作用等问题.
结论:
- 尽管存在文化和制度上的差异,但在5个研究国家中观察到前列腺癌治疗偏好的显著一致性.
- 确定了两个不同的患者偏好类别,主要关注点不同,但不是临床因素.
- 患者和临床医生之间关于治疗选择的加强沟通是必不可少的,特别是考虑到已识别的患者类和他们不同的关注点.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...